Comparison of 123I-metaiodobenzylguanidine (MIBG) and 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 56, Issue 7, 2011, Pages 1041-1045

  Naranjo, Arlene ^a   Parisi, Marguerite T ^b   Shulkin, Barry L ^c   London, Wendy B ^d   Matthay, Katherine K ^e   Kreissman, Susan G ^f   Yanik, Gregory A ^g  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

COG A3973; Curie score

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; (3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DIAGNOSTIC AGENT; DOXORUBICIN; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; EVENT FREE SURVIVAL; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; AUTOTRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; MALE; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCINTISCANNING; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INFANT; IODINE RADIOISOTOPES; MALE; NEUROBLASTOMA; RADIOPHARMACEUTICALS; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 79954494390     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22991     Document Type: Article

References (35)

1. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997; 33: 2130-2135.
2. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-1173.
3. Kreissman SG, Villablanca JG, Diller L, et al. Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neurolastoma (HR-NB): A Children's Oncology Group (COG A3973) study. J Clin Oncol 2007; 25: 9505. Annual Meeting Proceedings.
4. Wieland DM, Mangner TJ, Inbasekaran MN, et al. Adrenal medulla imaging agents: A structure distribution relationship study of radiolabeled aralkylguanidines. J Med Chem 1984; 27: 149-155.
5. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981; 305: 12-17.
6. McEwan AJ, Shapiro B, Sisson JC, et al. Radio-iodobenzylguanidines for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 1985; 15: 132-153.
7. Shapiro B, Copp JE, Sisson JC, et al. Iodine-131 meta-iodobenzylguanidine for the locating of suspected pheochromocytoma: Experience in 400 cases. J Nucl Med 1985; 26: 576-585.
8. Chatal JF, Charbonnel B. Comparison of iodobenzylguanidine in locating pheochromocytoma. J Clin Endocrinol Metab 1985; 61: 769-772.
9. Treuner J, Feine U, Niethammer D, et al. Scintigraphic imaging of neuroblastoma with 131-I iodobenzylguanidine. Lancet 1984; 1: 333-334.
10. Hoefnagel CA, Voûte PA, de Kraker J, et al. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenyl-guanidine. J Nucl Med 1987; 28: 308-314.
11. Munkner T. 131-I-metaiodobenzylguanidine scintigraphy of neuroblastomas. Semin Nucl Med 1985; 15: 154-160.
12. Edeling CJ, Buchler Frederickson P, Kamper J, et al. Diagnosis and treatment of neuroblastoma using 131-I-Metaiodobenzyguanidine. Nuklearmedizin 1986; 25: 172-175.
13. Wiseman GA, Pacak K, O'Dorisio MS, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: Results from a prospective multicenter trial. J Nucl Med 2009; 50: 1448-1454.
14. Vik TA, Pfluger T, Kadota R, et al. 123I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 2009; 52: 784-790.
15. Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzyl-guanidine (MIBG) and of 123I-MIBG: Clinical implications of the use of 123I-MIBG. Med Pediatr Oncol 1987; 15: 170-177.
16. Lumbroso JD, Guermazi F, Hartmann O, et al. Metaiodobenzylguanindine (mIBG) scans in neuroblastoma: Sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res 1988; 271: 689-705.
17. Claudiani F, Stimamiglio P, Bertolazzi L, et al. Radioiodinated meta-iodobenzylguanindine in the diagnosis of childhood neuroblastoma. Q J Nucl Med 1995; 39: 21-24.
18. Hadley GP, Rabe E. Scanning with iodine-131 MIBG in children with solid tumors: An initial appraisal. J Nucl Med 1986; 27: 620-626.
19. Lastoria S, Maurea S, Caracò C, et al. Iodine-131 metaiodobenzylguanindine scintigraphy for localization of lesions in children with neuroblastoma: Comparison with computed tomography and ultrasonography. Eur J Nucl Med 1993; 20: 1161-1167.
20. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39: 679-688.
21. Ady N, Zucker JM, Asselain B, et al. A new 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31A: 256-261.
22. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123 I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003; 21: 2486-2491.
23. Messina JA, Cheng SC, Franc BL, et al. Evaluation of semi-quantitative scoring systems for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006; 47: 865-874.
24. Perel Y, Conway J, Kletzel M, et al. Clinical impact and prognostic value of metaiodobenzylguanindine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 1999; 21: 13-18.
25. Suc A, Lumbroso J, Rubie H, et al. Metastatic neuroblastoma in children older than 1 year. Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996; 77: 805-811.
26. Kushner BH, Yeh SD, Kramer K, et al. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003; 21: 1082-1086.
27. Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma. A report for the International Neuroblastoma Risk Group (INRG) task force. Br J Cancer 2010; 102: 1319-1326.
28. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998; 16: 953-965.
29. Frappaz D, Bonneu A, Chauvot P, et al. Metaiodobenzylguanindine assessment of metastatic neuroblastoma: Observer dependency and chemo-sensitivity evaluation. The SFOP Group. Med Pediatr Oncol 2000; 34: 237-241.
30. Schmidt M, Simon T, Hero B, et al. The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008; 44: 1552-1558.
31. Boubaker A, Delaloye AB. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med 2008; 52: 388-402.
32. Katzenstein HM, Cohn SL, Shore RM, et al. Scintigraphic response by 123 I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004; 22: 3909-3915.
33. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
34. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II: Analysis and examples. Br J Cancer 1977; 35: 1-39.
35. Allison PD, editor. Survival analysis using the SAS® system: A practical guide. Cary, NC: SAS Institute, Inc.; 1995.